

ASX Release

Appointment of Marjan Mikel as Non-Executive Director

Sydney, Thursday 7 June 2018

Memphasys (ASX: MEM) reports that it has appointed Mr Marjan Mikel as an independent non-executive director. Mr Mikel replaces Mr John Pereira who has resigned. Mr Pereira was appointed as a non-executive director on 30 August 2016.

Mr Mikel (M Com, BSc (Hons), Dip Ed, MAICD), has had extensive experience in the pharmaceutical and medical device industries. He has worked in international sales, business development and at general manager and executive board level for Merck and Co and for Searle – Pharmacia. He has also worked internationally, ultimately as an executive board member for IMS Consulting and Services Japan, AsiaPac and ANZ, developing product and portfolio strategies for pharmaceutical and healthcare client companies. More recently he has focused on developing small, innovative businesses. He founded and subsequently sold Healthy Sleep Solutions after developing it into a successful business, with Resmed Ltd as a joint venture/shareholder partner. He is also a non-executive director of a number of small companies predominantly involved in developing medical devices and diagnostics.

The board members of Memphasys wish to thank Mr Pereira for his services and wish him well in his future endeavors.

For further information please contact:

Alison Coutts
Executive Chairman
+61 2 8415 7300
alison.coutts@memphasys.com

About Memphasys:

Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.